Soleus Capital Management L.P. Has $25.12 Million Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC)

Soleus Capital Management L.P. boosted its holdings in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 5.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,978,942 shares of the company's stock after buying an additional 374,946 shares during the quarter. C4 Therapeutics makes up approximately 1.6% of Soleus Capital Management L.P.'s investment portfolio, making the stock its 20th largest position. Soleus Capital Management L.P. owned approximately 9.89% of C4 Therapeutics worth $25,124,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Sei Investments Co. acquired a new stake in C4 Therapeutics during the 4th quarter valued at $45,000. Kazazian Asset Management LLC bought a new position in shares of C4 Therapeutics in the fourth quarter valued at about $51,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of C4 Therapeutics during the 4th quarter worth about $54,000. ProShare Advisors LLC boosted its holdings in shares of C4 Therapeutics by 83.1% during the 4th quarter. ProShare Advisors LLC now owns 20,283 shares of the company's stock worth $73,000 after buying an additional 9,204 shares during the period. Finally, Lazard Asset Management LLC acquired a new position in C4 Therapeutics in the 4th quarter valued at about $81,000. 78.81% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, UBS Group upgraded shares of C4 Therapeutics to a "hold" rating in a research report on Friday, February 14th.

C4 Therapeutics Stock Up 0.7%

Shares of C4 Therapeutics stock traded up $0.01 during trading on Thursday, reaching $1.37. The company's stock had a trading volume of 663,750 shares, compared to its average volume of 1,393,113. The business's 50-day moving average price is $1.55 and its 200-day moving average price is $3.02. C4 Therapeutics, Inc. has a 52 week low of $1.09 and a 52 week high of $7.66. The firm has a market cap of $97.28 million, a PE ratio of -0.81 and a beta of 3.10.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.11. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%. The firm had revenue of $7.20 million during the quarter, compared to the consensus estimate of $3.54 million. Equities analysts predict that C4 Therapeutics, Inc. will post -1.52 earnings per share for the current year.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.